"Designing Growth Strategies is in our DNA"
Surgical site infections are most commonly observed amongst patients underwent for surgery and are responsible for unplanned readmission in hospitals, added operating costs, and extended hospital stays. Pathogenic contamination of wound due to surgical procedures and weak immune resistance to bacteria are the basic factors for causing surgical site infections.
Along with infections caused during surgical procedures, certain other factors such as the patient being overweight, smoking, patient with cancer, diabetes, and patient with weak immune systems are responsible for causing the surgical site infection. According to the Centres for Disease Control and Prevention (CDC), there are three levels of surgical site infections, superficial incisional, deep incisional, and space infection.
To gain extensive insights into the market, Request for Customization
Every level of surgical site infection has different symptoms and indications. Surgical site infections are mostly treated with antibiotics; however, sometimes, additional procedures are required to treat the surgical site infection. Rapidly increasing geriatric population with compromised immunity and rise in the number of surgical procedures performed across the globe are likely to fuel the growth of the global surgical site infection treatment market during the forecast period.
Rising prevalence of surgical site infections is prominently driving the growth of the global surgical site infections treatment market. Also, certain factors such as climbing number of surgical procedures, aging population, and lack of preventive care in emerging nations leverages lucrative opportunity for growth of surgical site infections market in coming years.
According to a survey conducted by Public Health England, during 2016-2017, higher risk of surgical site infection was observed in large bowel surgery while the minimal risk was observed in hip & knee replacement surgery in the U.K. Growing awareness about the preventive measures for surgical infections are likely to drive the growth of the global surgical site infection treatment market by 2026.
However, reluctance for implementation of standard norms for surgical procedures, difficulty in identifying the surgical site infection, and lack of healthcare infrastructure in emerging nations are likely to hamper the growth of the global surgical site infections treatment market during the forecast period.
Some of the major companies that are present in the global surgical site infections treatment market are BD, 3M, B. Braun Melsungen AG, PAUL HARTMANN AG, SSIP, LLC, Covalon Technologies Ltd., Prescient Surgical, Medtronic, Stryker, STERIS plc., Medica Europe BV, Mölnlycke Health Care AB, Winner Medical Group Inc. and Others.
SEGMENTATION | DETAILS |
By Product | · Wound Care Dressings · Clippers · Antibiotic Prophylaxis Products · Antiseptics & Disinfectants · Surgical Drapes · Wound Irrigation Products · Others |
By Type | · Superficial Incisional Infection · Deep Incisional Infection · Space Infection |
By Phase | · Preoperative Phase · Intraoperative Phase · Postoperative Phase |
By End User | · Hospitals · Clinics · Ambulatory Surgery Centres · Others |
By Geography | · North America (U.S. and Canada) · Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) · Latin America (Brazil, Mexico, and Rest of Latin America) · Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa) |
In terms of product, antibiotic prophylaxis product segment is anticipated to hold the largest share in global surgical site infection market during the forecast period owing to high cost of the antibiotics, accepatnce of antibiotics as most established preventive method for surgical site infections, and patient friendly dosage forms such as tablet, capsules etc. available postoperative care
Geographically, the global surgical site infections treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe dominated global surgical site infections treatment market during the forecast period owing to well-developed healthcare infrastructure, growing investments in research activities by many key players in developing innovative treatment of surgical site infection. Additionally, new product launches by significant players with growing acquisitions and mergers are likely to fuel the growth of surgical site Infections treatment market in the North America region. In the Asia Pacific region, the surgical site Infections treatment market is anticipated to expand at a significant rate owing to the growing patient pool, rising awareness by government organizations, and growing prevalence of surgical site infections. Latin America and Middle East & Africa regions are likely to expand at considerable growth rate in surgical site infection treatment market during the forecast period.
US +1 833 909 2966 ( Toll Free )